THE European Medicines
Agency (EMA) has recommended
granting marketing authorisations
in the European Union (EU)
for Cabometyx (cabozantinib)
and Kisplyx (lenvatinib) for the
treatment of advanced renal cell
carcinoma (kidney cancer).
Both new products are classified
as tyrosine kinase inhibitors which
block certain enzymes known as
tyrosine kinases critical to the
growth of cancer cells and found on
the surface of the cells.The above article was sent to subscribers in Pharmacy Daily's issue from 26 Jul 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 26 Jul 16
DEMENTIA Australia has appointed comedian Geraldine Hickey (pictured) as its newest Ambassador, coinciding with the Melbourne Memory Walk & Jog event taking place this Sun.
NEW research from the Monash Addiction Research Centre has highlighted a critical shortfall in the availability of Naloxone, a life-saving medication that reverses opioid overdoses, across community pharmacies in Australia’s most populous states.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.